Medpace Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view top-rated stocks.

Wall Street analysts have given Medpace a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medpace wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 25th 2021.
View our earnings forecast for Medpace.

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Sunday, July, 25th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.07. Medpace had a trailing twelve-month return on equity of 21.74% and a net margin of 17.07%.
View Medpace's earnings history.

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 111.9% and is now trading at $177.23.
View which stocks have been most impacted by COVID-19.

Medpace updated its FY 2021 earnings guidance on Monday, August, 2nd. The company provided EPS guidance of $4.310-$4.500 for the period, compared to the Thomson Reuters consensus estimate of $4.380. The company issued revenue guidance of $1.11 billion-$1.15 billion, compared to the consensus revenue estimate of $1.13 billion.

3 analysts have issued twelve-month target prices for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they expect Medpace's stock price to reach $190.97 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medpace include Bitcoin Group (BTGGF), Charles River Laboratories International (CRL), Exact Sciences (EXAS), Incyte (INCY), PPD (PPD), ICON Public (ICLR), PRA Health Sciences (PRAH), Syneos Health (SYNH), Zymergen (ZY), National Research (NRC), Anavex Life Sciences (AVXL), Starpharma (SPHRY), Inotiv (NOTV), Luna Innovations (LUNA) and CM Life Sciences II (CMII).
View all of MEDP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (1.47%), Fisher Asset Management LLC (0.82%), Rice Hall James & Associates LLC (0.47%), Scout Investments Inc. (0.30%), Alliancebernstein L.P. (0.27%) and RE Advisers Corp (0.17%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig and Wedbush Securities Inc.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Ziegler Capital Management LLC, Rice Hall James & Associates LLC, Boston Trust Walden Corp, RE Advisers Corp, Scout Investments Inc., State of Michigan Retirement System, We Are One Seven LLC, and Fisher Asset Management LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, New Mexico Educational Retirement Board, Alliancebernstein L.P., Oregon Public Employees Retirement Fund, Exchange Traded Concepts LLC, Cooper Financial Group, and Texas Permanent School Fund. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $177.23.

Medpace has a market capitalization of $6.35 billion and generates $925.92 million in revenue each year. The company earns $145.38 million in net income (profit) each year or $4.00 on an earnings per share basis.

Medpace employs 3,600 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911 or via email at [email protected]